In the phase 1b-2 PANACEA Keynote-014 trial, pembrolizumab in combination with trastuzumab was evaluated in trastuzumab-resistant, advanced, and HER2+ breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.